Summary
46 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 13 USD is left as net profit.
- Revenue grew by 12% a year over the last 3 years.
What to watch
- Repaying its net debt would take 9.1 years of operating profit.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 118.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
Revenue grew by 12% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 20 USD
- Research and development 43 USD
- Sales and administration 26 USD
- Taxes and other -1.6 USD
- Net profit 13 USD
Net profit, industry median (Medical - Distribution) 1.4 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Royalty Revenues 100%
By region
The company reports no revenue by region.
Royalty Revenues brings in 100% of revenue.
Segments in detail